Opinions
Laura Wallace
Barr Laboratories
BRL-N
BUY
Jul 20, 2006
Has come off sharply but she is still buying. There were delays in the FDA in getting some of its drugs approved. Earnings will continue to be delivered and thinks their drug will be approved. Good value.
$46.370
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
A generic manufacturer, so unlike big pharmas that suffer when things come off, they actually benefit. Just picked up Allegra which is coming off patent. A great growth vehicle with a lot of drugs coming off patent in the next several years. Great exposure in women's health products.
biotechnology
pharmaceutical
TOP PICK
Generic drug manufacturer. Earnings are growing in the 20/25% range. Generics are the beneficiaries of the push to control the accelerating healthcare costs in the US. Have a good record of acquiring new generics and delivering them in a very cost effective way. No debt on the balance sheet. Great operating margins in the 35/38% range.
biotechnology
pharmaceutical